The polymorphic oxidation of beta-adrenoceptor antagonists
References (88)
- et al.
High plasma concentrations of beta-adrenoceptor blocking drugs and deficient hydroxylation
Lancet
(1982) - et al.
Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol l'-hydroxylase activities
Biochem. Pharmac.
(1985) - et al.
Oxidation polymorphism has clinical relevance
Lancet
(1984) - et al.
Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)
Biochem. biophys. Res. Commun.
(1984) - et al.
Debrisoquine/sparteine-type polymorphism of drug oxidation: Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol
J. biol. Chem.
(1986) - et al.
Determination of (R)- and (S)-alprenolol and (R)- and (S)-metoprolol as their diastereoisomeric derivatives in human plasma by reversed-phase liquid chromatography
J. Chromatogr.
(1982) - et al.
Beta-adrenoceptor blocking drugs: adverse reactions and interactions
Pharmac. Ther.
(1983) - et al.
Metoprolol oxidation by rat liver microsomes: inhibition by debrisoquine and other substances
Biochem. Pharmac.
(1986) - et al.
Polymorphic hydroxylation of debrisoquine in man
Lancet
(1977) - et al.
Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs
Life Sci.
(1984)
Inhibition of ethinyloestradiol and tolbutamide metabolism by quinoline derivatives in vitro
Chem. biol. Interact.
(1986)
Beta-blokers and drug oxidation status
Lancet
(1982)
Irreversible binding and metabolism of propranolol by human liver microsomes—relationship to polymorphic oxidation
Biochem. Pharmac.
(1987)
Polymorphic hydroxylation of debrisquine
Lancet
(1977)
Stereoselective delivery and actions of beta-receptor antagonists
Biochem. Pharmac.
(1988)
In vitro assessment of the mouse as an experimental model for the polymorphic oxidation of metoprolol
Br. J. Pharmac.
(1989)
Covalent binding of propranolol to rat and human liver microsomes: relation to inhibition of lignocaine metabolism
Br. J. Pharmac.
(1985)
Treatment of hypertension with beta-blocking drugs
Jl R. Coll. Phys.
(1982)
Pharmacocinetique de deux medicaments beta-bloquants: detection d'une anomalie pharmacogenetique
Schweiz. Med. Wochenschr.
(1976)
Assessing new drugs
Practitioner
(1983)
Metabolism of metoprolol-(3H) in man, the dog and the rat
Acta pharmac. tox.
(1975)
Adverse effects from metoprolol are not generally associated with oxidation status
Br. J. clin. Pharmac.
(1984)
Effect of route of administration on the relationship between beta-adrenergic blockade and plasma propranolol levels
Clin. Pharmac. Ther.
(1972)
Plasma propranolol levels in the qualitative measurement of beta-adrenergic blockade
Br. Med. J.
(1970)
The effects of antyihypertensive therapy on the quality of life
N. Engl. J. Med.
(1986)
Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers
Br. J. clin. Pharmac.
(1982)
Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents
Eur. J. clin. Pharmac.
(1983)
Consequence pharmacocinetique et clinique du polymorphisme genetique de l'oxydation
Schweiz. Med. Wochenschr.
(1983)
Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol
Eur. J. clin. Pharmac.
(1985)
Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentrations and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol
Eur. J. clin. Pharmac.
(1985)
Stereo- and regioselectivity of hepatic oxidation in man—effect of debrisoquine/sparteine phenotype on bufuralol hydroxylation
Eur. J. clin. Pharmac.
(1986)
Polymorphic drug oxidation—much ado about nothing?
Lancet
(1984)
The genetic polymorphism of sparteine oxidation
Xenobiotica
(1986)
A family and population study of the genetic polymorphism of debrisoquine in a white British population
J. med. Genet.
(1980)
Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol
Br. J. Pharmac.
(1971)
Determination of bufuraolol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection
Biomed. Mass Spectrom.
(1976)
Kinetics and metabolism of (+)-, (-)- and (+/-)-bufuralol
Eur. J. clin. Pharmac.
(1982)
Respiratory effects of timolol
N. Engl. J. Med.
(1985)
Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing
Br. J. Clin. Pharmac.
(1982)
The effect of impaired renal function on plasma levels and urinary excretion of metoprolol metabolites
Clin. Pharmacokinet.
(1980)
Metoprolol and debrisoquine metabolism in Nigerians: lack of evidence for polymorphic oxidation
Clin. Pharmac. Ther.
(1986)
Lack of evidence for polymorphism in metoprolol metabolism
Br. J. clin. Pharmac.
(1983)
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices
Br. J. clin. Pharmac.
(1986)
Cited by (23)
Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine
2000, Pharmacology and TherapeuticsImpact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs
1997, Advanced Drug Delivery ReviewsA rapid and sensitive electron-capture gas chromatographic procedure for analysis of metoprolol in rat brain and heart
1997, Journal of Pharmacological and Toxicological MethodsInteraction of metoprolol and fluoxetine
1993, The LancetThe role of individual human cytochrpmes P450 in drug metabolism and clinical response
1992, Trends in Pharmacological Sciences
Copyright © 1989 Published by Elsevier Inc.